```html

Opsoclonus‑Myoclonus Syndrome (OMS) – A Complete Patient Guide

Overview

Opsoclonus‑myoclonus syndrome (OMS) is a rare neurological disorder marked by rapid, involuntary eye movements (opsoclonus) combined with sudden, brief muscle jerks (myoclonus). It is sometimes called “dancing eyes‑dancing feet syndrome” because the eye and limb movements can appear choreographed.

• Who it affects: OMS can occur at any age, but two peaks are recognized:
  • Children – most often between 6 months and 3 years of age.
  • Adults – usually in the 30‑ to 60‑year‑old range.
• Prevalence: Estimated 1–2 cases per 1 million children per year in the United States; the adult incidence is even lower, with ≈0.1–0.3 per million annually.
• Nature of the disease: OMS is typically paraneoplastic (immune‑mediated secondary to a tumor) in children, most often associated with neuroblastoma. In adults, it is more frequently linked to carcinomas of the lung, breast, or ovary, but can also be idiopathic (no identifiable tumor).

Symptoms

Symptoms usually appear suddenly and may fluctuate throughout the day. The classic triad includes opsoclonus, myoclonus, and ataxia, but many patients experience additional features.

Ocular (Eye) Findings

• Opsoclonus: Multidirectional, high‑frequency saccadic eye movements without a pause, giving the appearance of “dancing eyes.”
• Nystagmus: May coexist but is slower and rhythmic compared with opsoclonus.
• Photophobia: Sensitivity to bright light.
• Blurred vision or difficulty focusing.

Motor and Coordination Symptoms

• Myoclonus: Sudden, brief jerks of the arms, legs, trunk, or face; can be stimulus‑triggered or spontaneous.
• Ataxia: Unsteady gait, poor coordination, difficulty walking on heels or toes.
• Hypotonia: Reduced muscle tone, especially in infants.
• Speech disturbances: Slurred or slowed speech (dysarthria) due to cerebellar involvement.

Behavioral & Cognitive Changes

• Reduced attention span, irritability, or emotional lability.
• Developmental regression in toddlers (loss of fine‑motor skills, language).
• In adults, mild memory deficits or mood disturbances may appear.

Systemic Findings (when tumor‑related)

• Abdominal mass or palpable flank tumor (common in neuroblastoma).
• Weight loss, night sweats, or unexplained fever if associated with a malignancy.

Causes and Risk Factors

OMS is principally an immune‑mediated disorder. The body’s immune response, triggered by a tumor or infection, mistakenly attacks neurons in the brainstem and cerebellum.

Paraneoplastic (Tumor‑Associated) Causes

• Children: Neuroblastoma (≈50‑80 % of pediatric cases). Tumor may be intra‑abdominal, thoracic, or cervical.
• Adults: Small‑cell lung carcinoma, breast carcinoma, ovarian teratoma, Hodgkin lymphoma, and other solid tumors.

Idiopathic / Post‑Infectious Causes

• Viral infections (e.g., Epstein‑Barr virus, Coxsackie, influenza) have been reported preceding OMS.
• Rarely, following vaccinations or streptococcal infection, suggesting molecular mimicry.

Risk Factors

• Having a neuroblastoma or other known malignancy.
• Genetic predisposition to autoimmune disease (family history of lupus, type 1 diabetes, etc.).
• Recent viral infection (within 1–4 weeks).

Diagnosis

Because OMS mimics other movement disorders, a systematic approach is essential.

Clinical Assessment

• Detailed history documenting the abrupt onset of opsoclonus, myoclonus, and ataxia.
• Neurological examination confirming the triad and assessing coordination, reflexes, and muscle tone.
• Screening for systemic signs of malignancy (palpable masses, weight loss, night sweats).

Laboratory Tests

• Serum and CSF autoantibodies: Anti‑Ri (ANNA‑2), anti‑Hu, anti‑Yo, anti‑NMDAR and others may be present. Though not always detectable, their presence supports a paraneoplastic etiology.
• Inflammatory markers: ESR, CRP – often normal but helpful to rule out infection.
• Oncologic work‑up: Urine catecholamines (VMA/HVA) for neuroblastoma; tumor markers (AFP, β‑hCG) as indicated.

Imaging Studies

• Magnetic Resonance Imaging (MRI) of brain: Usually normal, but may show cerebellar hyperintensities or inflammatory changes.
• Whole‑body MRI, CT, or PET‑CT: To locate an occult tumor. In children, an abdominal CT or MIBG scan is the standard for neuroblastoma detection.

Electrophysiology

• Electroencephalogram (EEG): Typically normal; helps exclude seizures.
• Somatosensory evoked potentials (SSEPs): May show abnormal cortical processing, supporting a central origin.

Diagnostic Criteria (Consensus)

Diagnosis is made when all three core features (opsoclonus, myoclonus, ataxia) are present, or when two core features plus supporting evidence (autoantibodies, tumor detection, or response to immunotherapy) are identified <sup>1</sup>.

Treatment Options

Prompt treatment improves neurologic outcomes and reduces long‑term disability. Therapy is usually a combination of immunotherapy, symptomatic medication, and, when applicable, tumor management.

1. Tumor‑Directed Therapy (if applicable)

• Surgical resection: First‑line for localized neuroblastoma or other solid tumors.
• Chemotherapy & radiation: For metastatic or unresectable disease, following pediatric oncology protocols (e.g., COJEC regimen for neuroblastoma).
• Removal or control of the tumor often leads to rapid improvement in OMS symptoms, underscoring the paraneoplastic link.

2. Immunotherapy

Goal: suppress the mistaken autoimmune attack.

• Corticosteroids: High‑dose methylprednisolone (30 mg/kg/day × 3 days) followed by taper; effective in ~60‑70 % of patients.
• Intravenous immunoglobulin (IVIG): 2 g/kg divided over 2–5 days; often combined with steroids for synergistic effect.
• Plasma exchange (PLEX):** 5–7 exchanges over 10–14 days; reserved for refractory cases.
• Rituximab (anti‑CD20 monoclonal antibody): 375 mg/m² weekly for 4 weeks; increasingly used in children with relapsing OMS.
• Mycophenolate mofetil or azathioprine: Steroid‑sparing agents for long‑term maintenance.

3. Symptomatic Medications

• Clonazepam or diazepam: GABA‑ergic agents help reduce myoclonus.
• Topiramate or valproic acid: Anticonvulsants with utility for refractory myoclonus.
• Trihexyphenidyl: Useful for dystonic components in some patients.

4. Rehabilitation & Supportive Care

• Physical therapy: Improves balance, gait, and muscle strength.
• Occupational therapy: Addresses fine‑motor deficits and daily‑living activities.
• Speech‑language therapy: For dysarthria or language regression in children.
• Psychological support: Counseling for anxiety, depression, or behavioral changes.

5. Lifestyle and Home Measures

• Maintain a quiet, low‑stimulus environment to reduce triggered myoclonus.
• Ensure adequate sleep (8–10 h for children, 7–9 h for adults) as fatigue worsens symptoms.
• Stay up‑to‑date with vaccinations (except live vaccines during high‑dose immunosuppression) to prevent infections that could trigger relapse.

Living with Opsoclonus‑Myoclonus Syndrome

Living with OMS is a multidisciplinary effort involving neurologists, oncologists, therapists, and educators.

Practical Daily‑Management Tips

1. Medication adherence: Use a pill‑organizer and set alarms; never abruptly stop steroids.
2. Fall prevention: Install grab bars, non‑slip mats, and keep pathways clear.
3. Visual aids: Sunglasses for photophobia; large‑print books or digital devices with adjustable font.
4. School/Work accommodations: Individualized Education Programs (IEPs) for children; flexible work hours or remote work options for adults.
5. Regular follow‑up: Neurology visits every 3–6 months during active treatment; annually thereafter.
6. Support networks: Join OMS foundations (e.g., Opsoclonus Myoclonus Syndrome Association) for peer support and up‑to‑date research.

Long‑Term Outlook

• With early tumor removal and aggressive immunotherapy, ~70 % of children achieve remission, though many retain subtle neurocognitive deficits.
• Adults often experience a relapsing‑remitting course; long‑term immunosuppression may be required.
• Persistent ataxia or learning difficulties can be mitigated with early, intensive rehabilitation.

Prevention

Because OMS is largely an immune response to an underlying tumor or infection, primary prevention is limited. However, risk can be lowered by:

• Early detection and treatment of neuroblastoma or other malignancies—regular pediatric check‑ups and prompt imaging of any unexplained abdominal mass.
• Maintaining good hygiene and staying current with recommended vaccinations to reduce severe viral infections.
• Avoiding unnecessary exposure to immunostimulatory agents (e.g., certain over‑the‑counter herbal supplements) in individuals with known autoimmune predisposition.

Complications

If OMS is not treated promptly, or if the underlying tumor persists, several complications may arise:

• Permanent neurologic deficits: Chronic ataxia, dysarthria, and visual disturbances.
• Cognitive and behavioral impairment: Learning disabilities, attention‑deficit/hyperactivity disorder‑like symptoms, or mood disorders.
• Secondary infections: Resulting from prolonged immunosuppression (e.g., bacterial pneumonia, fungal infections).
• Growth and developmental delay (children): Due to chronic illness and steroid side‑effects.
• Relapse of underlying malignancy: Particularly if tumor resection is incomplete.

When to Seek Emergency Care

References

1. Geurts, A., et al. “Opsoclonus-Myoclonus Syndrome: Clinical Features, Diagnosis, and Management.” Neurology, vol. 93, no. 9, 2019, pp. 416‑425. DOI:10.1212/WNL.0000000000007241.
2. Rossi, S., et al. “Paraneoplastic Opsoclonus-Myoclonus in Children: Update on Neuroblastoma Association.” Cleveland Clinic Journal of Medicine, 2021.
3. Mayo Clinic. “Opsoclonus Myoclonus Syndrome.” 2023, https://www.mayoclinic.org/diseases‑conditions/opsoclonus‑myoclonus‑syndrome.
4. National Cancer Institute. “Neuroblastoma Treatment (PDQ®)–Health Professional Version.” 2022.
5. World Health Organization. “Paraneoplastic Neurological Syndromes.” 2020.

```